Sarilumab

WASHINGTON — Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab than methotrexate, according to data presented at ACR Convergence 2024.

Patients with rheumatoid arthritis may be able to tame their disease progression and inflammation by adopting elements of the Mediterranean diet such as lowering sugar intake and incorporating protein in the form of fish or plant-based sources.

In this video, Sebastian E. Sattui, MD, MS, discusses exciting research on polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.

Among patients with polymyalgia rheumatica who relapse during glucocorticoid tapering, sarilumab is effective at enabling them achieve sustained remission and lowering cumulative glucocorticoid use, according to data.

The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition.

Patients with rheumatoid arthritis who achieve only a partial response with adalimumab demonstrate a low risk for worsened symptoms and a high likelihood of meaningful improvement when switching to sarilumab, according to data.

Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.

The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an inadequate response to, or cannot taper, corticosteroids, according to a press release from Sanofi.